AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 4 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - The expression of a growth factor that stimulates pituitary tumor growth tends to run concurrently with estrogen cycling, medical researchers say. By inhibiting estrogen production, tumor growth can be curbed, they indicate.
"The product of the pituitary tumor transforming gene (PTTG) exhibits in vitro and in vivo transforming activity, thereby modulating pituitary angiogenesis and tumor formation," said Anthony P. Heaney and coworkers at Cedars Sinai Medical Center, Los Angeles, California.
Heaney and associates showed in earlier studies that basic fibroblast growth factor (bFGF) and estrogen boost the production of pttg, and demonstrated that bFGF, in particular, could produce concurrent expression of pttg in pituitary tumors. The latest of the group's studies focused on the way estrogen modulates pttg production.
"Coincident with the circulating rat estradiol surge and maximal pituitary proliferation, pituitary pttg mRNA, bFGF, and VEGF expression increased approximately threefold during proestrus and estrus," Heaney and coauthors noted.
Other rodent analyses showed that when rodents were given concurrent administration of exogenous estrogen and an antiestrogen agent with mini-pumps, estrogen-associated stimulation of pttg fell. Not only that, prolactin levels fell by 88%, and the ...